3d Medicines (sichuan) Co., Ltd.
Clinical trials sponsored by 3d Medicines (sichuan) Co., Ltd., explained in plain language.
-
New immunotherapy combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing whether combining two drugs—Envafolimab (an immunotherapy injection) and Lenvatinib (a daily pill)—can shrink tumors in people with advanced solid cancers like lung, kidney, and liver cancer. About 170 adults whose cancer has worsened after standard treatmen…
Phase: PHASE1, PHASE2 • Sponsor: 3D Medicines (Sichuan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New immunotherapy shot targets tumors with many mutations
Disease control Recruiting nowThis phase 2 trial is testing Envafolimab, an immunotherapy drug given as a shot, in 126 adults with advanced solid tumors that have not responded to standard treatments. The study aims to see if patients with a high number of tumor mutations respond better than those with fewer …
Phase: PHASE2 • Sponsor: 3D Medicines (Sichuan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for advanced endometrial cancer: immunotherapy combo under study
Disease control Recruiting nowThis study tests two drugs, envafolimab (an immunotherapy) and lenvatinib (a targeted therapy), alone or together, in 108 people with advanced endometrial cancer that has worsened after standard chemotherapy. The main goal is to see if the drugs shrink tumors. Researchers will al…
Phase: PHASE2 • Sponsor: 3D Medicines (Sichuan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New shot shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis phase 2 trial is testing an immunotherapy drug called KN035, given as a shot under the skin, for people with advanced solid tumors that have specific genetic features (dMMR or MSI-H). The study includes 200 participants with colorectal cancer or other solid tumors who have a…
Phase: PHASE2 • Sponsor: 3D Medicines (Sichuan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo aims to shrink lung tumors before surgery
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug envafolimab to standard chemotherapy helps shrink tumors before surgery and delays cancer return in people with stage III non-small cell lung cancer. About 390 participants will receive either envafolimab plus chemo or a plac…
Phase: PHASE3 • Sponsor: 3D Medicines (Sichuan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC